Group 1 - WuXi Biologics (02269) announced the issuance of a total of 8.5314 million ordinary shares as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 8.5314 million ordinary shares as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Summary by Category - **Company Actions** - The company has exercised options leading to the issuance of 8.5314 million ordinary shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期： 2025年11月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | ...

Market Overview - Both Shanghai and Hong Kong markets opened lower but showed strong recovery, with the Shanghai Composite Index breaking the 4000-point mark, reaching a ten-year high [1] - The Hang Seng Index also surpassed 27000 points, with trading volume exceeding 270 billion [1] - The U.S. government shutdown has ended after 43 days, improving dollar liquidity and boosting both risk and safe-haven assets [1] Financial Data - As of October 31, the total social financing scale reached 437.72 trillion yuan, a year-on-year increase of 8.5% [3] - The broad money supply (M2) stood at 335.13 trillion yuan, growing by 8.2% year-on-year [3] - The narrow money supply (M1) was 112 trillion yuan, with a year-on-year growth of 6.2% [3] Commodity Prices - Prices for VC electrolyte additives have surged significantly, with the average price reaching 110,000 yuan/ton, an increase of 68% [4] - R32 prices have risen to 68,000 yuan/ton, benefiting companies like Dongyue Group, which saw a nearly 9% increase in stock price [5] Industry Developments - Several paper companies have announced price increases, driven by rising costs and expanding demand, particularly in the packaging paper sector [9] - The West Mande project in Guinea, which has the potential to become the fifth-largest iron ore mine, has commenced production, impacting the iron ore supply landscape [5] Company Highlights - Zhongyuan Marine Energy plans to acquire a large LPG transport vessel for 598 million yuan, aiming to enhance its position in the liquefied gas transportation sector [10] - The company reported a revenue of 5.47 billion yuan for Q3 2025, a year-on-year decrease of 2.5%, but a net profit increase of 4.4% [10] - Zhongyuan Marine Energy has secured long-term contracts that cover approximately 20 million tons of its total oil transportation volume, providing stable revenue [11][12]

Group 1 - The Hong Kong technology sector showed strength on November 13, with the Hang Seng Technology Index rising over 1.5% at one point, and the Hong Kong Stock Connect Technology Index increasing by more than 1.1% [1] - Major constituents such as BeiGene, Innovent Biologics, Hua Hong Semiconductor, CanSino Biologics, WuXi Biologics, and Alibaba saw significant gains [1] - The Tianhong Hong Kong Technology ETF (159128) closely tracks the Hong Kong Stock Connect Technology Index, allowing T+0 trading and is not restricted by QDII quotas, with a trading volume of 139 million yuan and a turnover rate of 21.43% on its first day [1] Group 2 - Alibaba has secretly launched the "Qianwen" project to develop a personal AI assistant app, Qianwen APP, based on the Qwen model, aiming to compete directly with ChatGPT [2] - Guotai Junan Securities predicts that the growth style will become the core allocation theme in the Hong Kong market due to global liquidity easing and the upward cycle of the technology industry [2] - The macro backdrop of a weak US dollar and accelerated independent innovation is expected to benefit growth assets in Hong Kong, with foreign capital inflow and policy dividends contributing to valuation recovery [2]

Core Viewpoint - The Tianhong Guozheng Hong Kong Stock Connect Technology ETF (code: 159128) was officially listed on November 13, 2023, and has shown active trading with a turnover of 7.83% and a transaction volume of 50.54 million yuan by midday [1]. Product Highlights - The Tianhong Hong Kong Technology ETF closely tracks the Guozheng Hong Kong Stock Connect Technology Index, which consists of the top 30 Hong Kong stocks highly related to technology themes, with the top ten constituents accounting for over 75% [2]. - The index focuses on "hard technology" and "new economy" sectors, with significant exposure to semiconductors, consumer electronics, and high-end manufacturing, while also covering internet and consumer technology [2]. - The PE valuation of the index is at the 38th percentile over the past five years, indicating a high margin of safety [2]. - The ETF aims to capture strategic opportunities in AI, smart vehicles, and innovative pharmaceuticals, with core assets still at historical low valuations [2]. Institutional Perspectives - As earnings reports are released, the resilience and recovery momentum of technology giants are expected to gradually emerge, with companies like Tencent, Meituan, JD Group, Bilibili, and SMIC set to announce their earnings [3]. - Southbound capital has continuously increased its holdings in the Hong Kong stock market, with a cumulative net purchase amount reaching 1.3 trillion HKD by November 11, 2023, which is 1.6 times last year's total [3]. - Despite some short-term fluctuations in the Hong Kong market, institutions believe this rally is not merely a temporary rebound, with expectations for continued steady progress driven by economic recovery signals and improved global liquidity [3].

Group 1 - The gold and innovative drug sectors continue to rise, with the gold ETF Huaxia increasing by 1.41% and the more elastic gold stock ETF rising by 3.12%, while the Hang Seng Pharmaceutical ETF gained 3.36%, marking two consecutive days of gains [1] - Spot gold rebounded to $4,196.54 per ounce, aiming for the $4,200 mark, following the signing of a federal government temporary funding bill by President Trump, which ended a 43-day government shutdown, improving dollar liquidity and boosting both risk and safe-haven assets [2] - BeiGene's stock surged over 6%, reaching a four-year high, with Q3 revenue of 10.077 billion yuan, a year-on-year increase of 41.1%, and both Q3 and year-to-date net profits turning positive [2] Group 2 - The gold ETF Huaxia (518850) tracks the SGE Gold 9999 Index with a total fee rate of 0.2%, the lowest in its category, while the gold stock ETF (159562) tracks SSH gold stocks, primarily consisting of gold and copper, with a similar fee rate [2] - The Hang Seng Pharmaceutical ETF (159892) represents the global pharmaceutical industry chain with a latest scale of 6.15 billion yuan, featuring top-weighted stocks including BeiGene, WuXi Biologics, and others [3] - Recent inflows into gold ETFs have been significant, with a net inflow of 1.26 billion yuan in a single day, and the Huaxia gold ETF attracting net inflows for 10 consecutive days, totaling 2.015 billion yuan over the past 20 days [2]

Core Viewpoint - The Hong Kong medical sector is experiencing significant growth, as evidenced by the performance of the Hong Kong Medical ETF, which has increased over 50% since its launch this year, indicating strong market resilience [1] Industry Summary - The CXO (Contract Research Organization) sector is seeing robust order volumes, with major companies like WuXi AppTec reporting an order backlog of 59.88 billion yuan, a year-on-year increase of 41.2% [2] - WuXi Biologics has an unfulfilled order total of 20.3 billion USD (approximately 147 billion yuan), showcasing strong demand in the sector [2] - Other CXO companies, such as Kanglong Chemical and Tigermed, are also reporting double-digit growth in new orders, driven by high demand from multinational pharmaceutical companies [2] Company Summary - ADC (Antibody-Drug Conjugate) related CDMO companies are experiencing significant growth, with Pharmaron reporting a 15% year-on-year increase in new CDMO orders, and orders for ADC-related new business growing over 100% [3] - BeiGene has shown remarkable performance, with a 10% increase in its US stock price following positive regulatory developments, indicating a favorable environment for pharmaceutical companies [5] - Pfizer has initiated a new clinical trial for a dual-target PD-1/VEGF antibody drug, signaling ongoing innovation in drug development [5]

Group 1 - The core viewpoint of the news highlights the continuous rise of innovative drugs in the Hong Kong stock market, driven by strong performance from companies like BeiGene and 3SBio, leading to a significant increase in the Hang Seng Innovative Drug ETF [1] - BeiGene reported Q3 revenue of 10.077 billion yuan, a year-on-year increase of 41.1%, and a net profit of 689 million yuan, marking a turnaround from losses [1] - The innovative drug sector is experiencing fundamental improvements due to policy support, performance realization, and accelerated international expansion, indicating significant mid-to-long-term investment value [1] Group 2 - A breakthrough in policy is noted with the introduction of a "commercial insurance innovative drug catalog" in the 2025 national medical insurance negotiations, which is expected to improve cash flow for pharmaceutical companies and optimize the payment ecosystem for innovative drugs [1] - The performance of leading pharmaceutical companies in Q3 2025 shows a transition from a "research and development investment phase" to a "commercialization harvest phase," with significant reductions in losses or profitability being achieved [1] - The international expansion of Chinese innovative drugs is accelerating, with total foreign licensing transactions exceeding 100 billion USD in the first ten months of 2025, reflecting the growing recognition of Chinese drug pipelines by multinational corporations [1] Group 3 - The Hang Seng Innovative Drug ETF (159316) has seen significant capital inflow, with a net inflow of 1.298 billion yuan over the past 20 days, bringing its total size to 4.178 billion yuan [3] - This ETF is the only product tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, focusing on core enterprises in the innovative drug industry, excluding CXO companies [3] - Key weighted stocks in the ETF include leading companies such as BeiGene, Innovent Biologics, WuXi Biologics, and CanSino Biologics, providing investors with a convenient tool for exposure to cutting-edge innovative drug companies in Hong Kong [3]

Core Insights - The Hong Kong stock market opened lower on November 12, with the Hang Seng Technology Index experiencing a slight pullback [1] - The Tianhong Hong Kong Technology ETF (159128) was officially listed and traded, with a transaction volume exceeding 20 million yuan [1] - The ETF closely tracks the Guozheng Hong Kong Stock Connect Technology Index, which consists of the top 30 Hong Kong stocks related to technology themes, covering areas such as AI, smart vehicles, and innovative pharmaceuticals [1] Market Performance - Among the constituent stocks, Baijia Shenzhou rose over 6%, while other notable gainers included Xinda Bio, Kangfang Bio, and WuXi Biologics [1] - As of November 11, the top 10 constituent stocks accounted for over 75% of the index, indicating a high concentration [1] Valuation Metrics - The current TTM price-to-earnings ratio of the Guozheng Hong Kong Stock Connect Technology Index is at the 36th percentile over the past five years, suggesting a historically low valuation level [1] - The ETF also includes off-market linked funds (A: 024885, C: 024886) [1] Economic Outlook - Expectations for interest rate cuts in the U.S. are rising, with a 67.6% probability of a 25 basis point cut in December according to CME FedWatch [2] - Analysts suggest that the Hong Kong stock market could reach new highs due to the influx of capital and the gathering of quality assets, with a focus on technology stocks [2] Market Sentiment - The foundation of the Hong Kong bull market remains intact, but the evolution is likely to be characterized by "volatile upward movement" rather than rapid increases [2] - The strong fundamental drivers in November highlight the importance of high-growth sectors, with opportunities emerging amid market fluctuations [2]